Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Heron Therapeutics Inc (HRTX) Price & Performance

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)Trade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Heron Therapeutics Inc — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.26 (market cap $39.95B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 539.6× Heron Therapeutics Inc's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and Heron Therapeutics Inc for 35 Days on average.

HLNHRTX
Market Cap
$39.95B$74.04M
Volume
18,243,5813,668,095
Sector
HealthHealth
52-Week High
$11.27$1.49
52-Week Low
$8.70$0.27
Typical Hold Time
0 Days35 Days
Enterprise Value
$49.77B$180.78M
Dividend Yield
2.2%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

No Aura AI signal available yet.

Heron Therapeutics Inc

HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.

The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLN
100% Buy0% Sell
Avg holding period · 0 Days
HRTX
8% Buy92% Sell
Avg holding period · 35 Days

About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.

Read more on HLN →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →